-
The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong CY, Liao AW, Papademetriou D, Nicolaides KH.
Prenat Diagn 2000;20:673-5. -
Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH.
Prenat Diagn 2000;20:495-9. -
Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation.
Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH.
Prenat Diagn 2000;20:411-6. -
One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester.
Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH.
BJOG 2000;107:1271-5. -
Early prediction of severe twin-to-twin transfusion syndrome.
Sebire NJ, Souka A, Skentou H, Geerts L, Nicolaides KH.
Hum Reprod 2000;15:2008-10. -
The 11-14 week scan.
Nicolaides KH, Heath V, Liao AW.
Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:581-94. -
Increased fetal nuchal translucency: possible association with esophageal atresia.
Brown RN, Nicolaides KH.
Ultrasound Obstet Gynecol 2000;15:531-2. -
Hyaluronan in the nuchal skin of chromosomally abnormal fetuses.
Bohlandt S, von Kaisenberg CS, Wewetzer K, Christ B, Nicolaides KH, Brand-Saberi B.
Hum Reprod 2000;15:1155-8. -
Pathophysiology of increased nuchal translucency in chromosomally abnormal fetuses.
von Kaisenberg CS, Brand-Saberi B, Jonat W, Nicolaides KH.
Der Gynäkologe 1999;32:193-199. -
Lymphatic vessel hypoplasia in fetuses with Turner syndrome.
von Kaisenberg CS, Nicolaides KH, Brand-Saberi B.
Hum Reprod 1999;14:823-6. -
Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta -hCG and PAPP-A at 10-14 weeks of gestation.
Tul N, Spencer K, Noble P, Chan C, Nicolaides K.
Prenat Diagn 1999;19:1035-42. -
A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;13:231-7. -
Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation.
Snijders RJ, Sebire NJ, Nayar R, Souka A, Nicolaides KH.
Am J Med Genet 1999;86:205-7. -
Nuchal translucency as a marker of congenital heart disease.
Perdu M, Hyett JA, Sharland G, Snijders RS, Nicolaides KH.
Contracept Fertil Sex 1999;27:I-V. -
Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks.
Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH.
Ultrasound Obstet Gynecol 1999;14:307-10. -
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study.
Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH.
BMJ 1999;318:81-5. -
Collagen type VI gene expression in the skin of trisomy 21 fetuses.
von Kaisenberg CS, Brand-Saberi B, Christ B, Vallian S, Farzaneh F, Nicolaides KH.
Obstet Gynecol 1998;91:319-23. -
Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a trisomy 16 mouse.
von Kaisenberg CS, Krenn V, Ludwig M, Nicolaides KH, Brand-Saberi B.
Anat Embryol 1998;197:105-24. -
Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation.
Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH.
Ultrasound Obstet Gynecol 1998;11:391-400. -
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation.
Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH.
Lancet 1998;352:343-6.